Morningstar Aandelenrapport

Nektar Therapeutics NKTR

Marges (% van omzet)
20192020202120222023
Inkomsten100,00%100,00%100,00%100,00%100,00%
Kosten van inkomsten18,65%12,74%24,43%23,50%37,47%
Brutomarge 81,35%87,26%75,57%76,50%62,53%
SG&A86,12%68,46%120,55%100,30%85,90%
Research and development379,15%267,26%392,78%237,17%126,67%
Exploitatiemarge -383,92%-248,45%-437,76%-260,97%-150,05%
Net Int, Inc and Other-767,85%-538,78%-951,24%-657,45%-456,58%
EBT-marge-383,93%-290,32%-513,49%-396,48%-306,54%
Winstgevendheid
20192020202120222023
Belastingtarief0,53%0,32%0,55%3,49%-0,22%
Nettomarge-384,47%-290,65%-514,03%-399,98%-306,31%
Rendement op activa -21,35-25,28-39,45-40,29-49,80
Financiële leverage1,411,431,641,943,04
Rendement op eigen vermogen -28,22-35,80-59,64-70,39-110,95
© Copyright 2024 Morningstar, Inc. Alle rechten voorbehouden.

Voorwaarden        Privacybeleid        Cookie Settings        Beleidsdocumenten